Clinical trials
Gemcitabine clinical trials
Below are recruiting gemcitabine clinical trials, each written for real people, not researchers. We’re tracking 373 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07213804RecruitingPhase 3
Study of sofetabart mipitecan for ovarian cancer
This trial tests a new drug called sofetabart mipitecan for people with ovarian cancer that has come back after treatment. It is for those whose cancer is either resistant to platinum chemo (Part A) or sensitive to it (Parts B and C). The study will see if the drug can help shrink or slow the cancer.
Birmingham, AlabamaAges 18 years+ - NCT07566156RecruitingPhase 3
New drug combination vs. radiation for bladder cancer preservation
This trial tests whether two drugs (enfortumab vedotin and pembrolizumab) work better than radiation with chemotherapy for muscle-invasive bladder cancer. The goal is to treat your cancer while keeping your bladder instead of removing it.
Santa Barbara, CaliforniaAges 18 years+ - NCT06957886RecruitingPhase 3
Study of BL-M07D1 vs chemo for HER2-low breast cancer
This trial tests a new drug, BL-M07D1, against standard chemotherapy for people with HER2-low breast cancer that has spread or come back. It aims to find which treatment works better.
Guangzhou, GuangdongAges 18–75 - NCT06821503RecruitingPhase 1/Phase 2
Study of LM-108 with chemo for advanced pancreatic cancer
This trial tests a new drug called LM-108 combined with chemotherapy for people with advanced pancreatic cancer that hasn't been treated before. The goal is to see if it's safe and may help shrink tumors or stop them from growing.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06904378RecruitingPhase 1/Phase 2
New drug combo for advanced pancreatic cancer
This trial tests a new drug called ONT01 combined with two standard chemo drugs (gemcitabine and nab-paclitaxel) for people with pancreatic cancer that has spread and is no longer responding to first treatment. The goal is to see if this new combination can help control the cancer.
St Louis, MissouriAges 18 years+ - NCT06752811RecruitingPhase 3
Testing a new paclitaxel formula for advanced pancreatic cancer
This trial tests a new form of the chemotherapy drug paclitaxel (called polymeric micellar paclitaxel) for people with pancreatic cancer that has spread to other parts of the body (metastatic). It's for those who haven't had any prior treatment for their metastatic cancer, and aims to see if this drug can help control the cancer.
Nanjing, JiangsuAges 18–75 - NCT06685796RecruitingPhase 2
New drug combo for advanced triple-negative breast cancer
This trial is testing a new drug called BEBT-209 combined with chemotherapy (carboplatin and gemcitabine) for people with advanced triple-negative breast cancer. It may be an option if you have had 1 or 2 prior treatments and your cancer is not controlled by standard therapies.
Guangzhou, GuangdongAges 18 years+ - NCT06182072RecruitingPhase 1
ProAgio for advanced pancreatic cancer
This trial tests a new drug called ProAgio combined with standard chemotherapy for people with stage IV pancreatic cancer. It aims to see if the combination is safe and effective.
Birmingham, AlabamaAges 18 years+ - NCT06280508RecruitingPhase 2
Perioperative chemo plus immunotherapy for bile duct cancer
This trial tests a combination of chemotherapy, immunotherapy (adebrelimab), and a targeted therapy (apatinib) before and after surgery for bile duct cancer that can be removed and has a high risk of coming back. It aims to see if this approach can lower the chance of recurrence.
Guangzhou, China/GuangdongAges 18 years+ - NCT06241781RecruitingPhase 2
Immune cells from your tumor for cervical cancer
This trial tests a new treatment using your own immune cells (called tumor-infiltrating lymphocytes) that are grown in a lab and given back to you. It is for people with cervical cancer that has come back or spread and hasn't been stopped by other treatments.
Beijing, Beijing MunicipalityAges 18–70 - NCT05978609RecruitingPhase 2
Testing cadonilimab plus chemotherapy for advanced bile duct cancer
This trial tests a new combination therapy for people with advanced bile duct or gallbladder cancer that can't be removed by surgery. It combines a drug called cadonilimab with standard chemotherapy to see if it works better than chemotherapy alone.
Chengdu, SichuanAges 18–75 - NCT05754853RecruitingPhase 3
MRG002 antibody compared with standard chemo for HER2 bladder cancer
This trial studies whether MRG002, a targeted antibody treatment, works better than the patient’s chosen standard chemotherapy. It is for people with HER2-positive advanced or metastatic urothelial (bladder/urinary tract) cancer whose disease has progressed after prior platinum chemotherapy and immunotherapy.
Beijing, Beijing MunicipalityAges 18–75 - NCT05634369RecruitingPhase 1/Phase 2
NK cell and chemotherapy trial for relapsed soft tissue sarcoma
This early-phase trial studies a type of immune cell treatment (NK cells) made from donor cells, given with chemotherapy drugs gemcitabine and docetaxel. It’s for children and young adults whose bone or soft tissue sarcoma has come back or hasn’t responded to prior treatment.
South Birmingham, AlabamaAges 2–40 - NCT04365036RecruitingPhase 3
Check if PD-1 plus chemo-radiation helps early nasal lymphoma
This trial studies whether adding toripalimab (an immune therapy that targets PD-1) to standard chemo-radiation works better for newly diagnosed early-stage nasal natural killer/T-cell lymphoma. It’s designed to see if the combined treatment can improve outcomes while staying safe.
Guangzhou, GuangdongAges 18–75 - NCT05279300RecruitingPhase 1
Study drug CS5001 for advanced solid tumors and B-cell lymphomas
This Phase 1 study tests how safe and effective CS5001 is for people with advanced (not curable by standard local treatment) solid tumors or B-cell lymphomas. It’s for cancers that have come back or worsened after prior standard treatments.
East Setauket, New YorkAges 18 years+ - NCT03547973RecruitingPhase 2
Study of sacituzumab govitecan for advanced or non-removable bladder cancer
This trial tests sacituzumab govitecan, an anti-cancer drug, for people with urothelial (bladder/urinary tract) cancer that has spread or can’t be removed with surgery. It’s designed for tumors that have been treated already in specific ways, to see if the medicine can shrink or control the cancer.
Tucson, ArizonaAges 18 years+ - NCT04495296RecruitingPhase 1/Phase 2
TST001 for advanced or metastatic solid tumors
This Phase 1/2 study tests TST001, and sometimes a combination with other cancer medicines, to see how safe it is and how well it may work in advanced or metastatic solid tumors. You might be eligible if you have certain tumor types and lab/health requirements, and if your tumor tissue shows specific marker results (depending on the study part).
Bengbu, AnhuiAges 18 years+ - NCT06472037RecruitingPhase 2
AG chemo plus immunotherapy and short radiation for locally advanced pancreatic cancer
This trial tests a combination of two chemotherapy drugs (AG) plus an immunotherapy (cadonilimab) and a short course of radiation for people with locally advanced pancreatic cancer that hasn't been treated yet. The goal is to see if this approach helps shrink or control the tumor.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT06204614Enrolling by invitationEarly Phase 1
Drug screening for bladder cancer before surgery
This trial tests a tiny device placed into bladder tumors before surgery to see which drugs might work best for each patient, helping guide future treatment choices.
Boston, MassachusettsAges 18–120 - NCT07450040Enrolling by invitation
Tislelizumab plus chemo for early-stage NK/T-cell lymphoma
This trial tests a combination of the immunotherapy drug tislelizumab with two chemotherapy drugs (gemcitabine and peraspartase) for people with newly diagnosed stage I or II NK/T-cell lymphoma. The goal is to see if this combination works well and is safe.
Shanghai, ChinaAges 18–70 - NCT06435429RecruitingPhase 3
Zanidatamab vs trastuzumab for HER2+ breast cancer
This study compares a new drug called zanidatamab against trastuzumab (Herceptin), both given with a chemotherapy of your doctor's choice. It is for people with HER2-positive breast cancer that has spread and who have already tried T-DXd treatment.
Phoenix, ArizonaAges 18 years+ - NCT06843447RecruitingPhase 1/Phase 2
Study of Raludotatug Deruxtecan for Ovarian Cancer
This study tests a new drug called raludotatug deruxtecan for people with ovarian cancer that has come back. It's designed for those whose cancer is either sensitive or resistant to platinum chemotherapy, and who have had 1-3 prior treatments.
New Haven, ConnecticutAges 18 years+ - NCT06250972RecruitingPhase 3
Radiotherapy for advanced pancreatic cancer with normal CA19-9 after chemo
This trial tests whether giving radiotherapy to the pancreas can help people with advanced pancreatic cancer whose CA19-9 level has dropped to normal after chemotherapy. It's for patients whose cancer is still locally advanced (hasn't spread to distant organs).
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06257017RecruitingPhase 2
Using DNA tests to guide chemotherapy after bladder cancer surgery
This trial checks if a DNA blood test can help decide who needs extra chemo after bladder or upper urinary tract cancer surgery. It tests whether watching for cancer DNA in the blood can match patients to the right treatment.
Hong Kong, Hong KongAges 18–70
Hear when a new Gemcitabine trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for gemcitabine?
- Yes. Clin2 currently lists 373 recruiting gemcitabine studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a gemcitabine trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a gemcitabine trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.